Fairmount Funds Management LLC: SPYRE THERAPEUTICS INC (SYRE): Quarterly 13F Position History
As of Q1 2026, Fairmount Funds Management LLC reported 4,018,101 shares of SPYRE THERAPEUTICS INC (SYRE), worth $202.7M and representing 14.6% of its 13F equity book. The position first appeared in Q3 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 4,018,101Shares Held (Latest Filing)
- $202.7MReported Market Value (Latest Filing)
- 14.6%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$71.0MQuarter-over-Quarter Value Change
- 4,018,101Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,018,101 | 0 | — | $202.7M | 14.6% | $50.4 |
| Q4 2025 | 4,018,101 | 0 | — | $131.6M | 10.0% | $32.8 |
| Q3 2025 | 4,018,101 | 0 | — | $67.3M | 6.1% | $16.8 |
| Q2 2025 | 4,018,101 | 0 | — | $60.2M | 7.8% | $15.0 |
| Q1 2025 | 4,018,101 | 0 | — | $64.8M | 10.1% | $16.1 |
| Q4 2024 | 4,018,101 | 0 | — | $93.5M | 9.3% | $23.3 |
| Q3 2024 | 4,018,101 | 0 | — | $118.2M | 9.6% | $29.4 |
| Q2 2024 | 4,018,101 | +3,639,680 | +961.8% | $94.5M | 10.7% | $23.5 |
| Q1 2024 | 378,421 | 0 | — | $14.4M | 1.6% | $37.9 |
| Q4 2023 | 378,421 | 0 | — | $8.1M | 0.9% | $21.5 |
| Q3 2023 | 378,421 | — | — | $4.6M | 0.6% | $12.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Fairmount Funds Management LLC first disclose a SYRE position in 13F-HR filings?
Fairmount Funds Management LLC first reported SPYRE THERAPEUTICS INC (SYRE) on its 13F-HR filing for the period ending 2023-09-30 (Q3 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in SYRE?
Fairmount Funds Management LLC held the same 4,018,101 shares of SYRE between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in SYRE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.